Abstract
Clinically significant bradycardia is an uncommon problem in children, but one that can cause significant morbidity and sometimes necessitates implantation of a pacemaker. The most common causes of bradycardia are complete heart block (CHB), which can be congenital or acquired, and sinus node dysfunction, which is rare in children with structurally normal hearts. Pacemaker is indicated as therapy for the majority of children with CHB, and while early mortality is lower in postnatally diagnosed CHB than in fetal CHB, it is still up to 16%. In young children, less invasive transvenous pacemaker systems can be technically challenging to place and carry a high risk of complications, often necessitating surgical epicardial pacemaker placement, which usually entails a median sternotomy. We report three cases of pediatric patients referred for pacemaker implantation for different types of bradycardia, treated at our institution with oral albuterol with therapeutic results that avoided the need for surgical pacemaker implantation at that time.
Similar content being viewed by others
References
Writing Committee Members, Shah MJ, Silka MJ et al (2021) 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients. Heart Rhythm 18(11):1888–1924. https://doi.org/10.1016/j.hrthm.2021.07.038
Michaëlsson M, Engle MA (1972) Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 4(3):85–101
Steinberg L (2023) Congenital heart block. Cardiol Clin 41(3):399–410. https://doi.org/10.1016/j.ccl.2023.03.002
Baruteau AE, Pass RH, Thambo JB, Behaghel A, Le Pennec S, Perdreau E, Combes N, Liberman L, McLeod CJ (2016) Congenital and childhood atrioventricular blocks: pathophysiology and contemporary management. Eur J Pediatr 175(9):1235–1248. https://doi.org/10.1007/s00431-016-2748-
Jaeggi ET, Hamilton RM, Silverman ED, Zamora SA, Hornberger LK (2002) Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution’s experience of 30 years. J Am Coll Cardiol 39(1):130–137. https://doi.org/10.1016/s0735-1097(01)01697-7
Michaëlsson M, Jonzon A, Riesenfeld T (1995) Isolated congenital complete atrioventricular block in adult life. A prospect study. Circulation 92(3):442–449. https://doi.org/10.1161/01.cir.92.3.442
Eronen M (2001) Long-term outcome of children with complete heart block diagnosed after the newborn period. Pediatr Cardiol 22(2):133–137. https://doi.org/10.1007/s002460010179
Fischbach PS, Frias PA, Strieper MJ, Campbell RM (2007) Natural history and current therapy for complete heart block in children and patients with congenital heart disease. Congenit Heart Dis 2(4):224–234. https://doi.org/10.1111/j.1747-0803.2007.00106.x
Berul CI (2008) Defibrillator indications and implantation in young children. Heart Rhythm 5(12):1755–1757. https://doi.org/10.1016/j.hrthm.2008.07.027
Carroll CL, Sala KA (2013) Pediatric status asthmaticus. Crit Care Clin 29(2):153–166. https://doi.org/10.1016/j.ccc.2012.12.001
Rachelefsky GS, Katz RM, Siegel SC (1982) Oral albuterol in the treatment of childhood asthma. Pediatrics 69(4):397–403
Price AH, Clissold SP (1989) Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs 38(1):77–122. https://doi.org/10.2165/00003495-198938010-00004
Evans CH, Duby JJ, Berry AJ, Schermer CR, Cocanour CS (2014) Enteral albuterol decreases the need for chronotropic agents in patients with cervical spinal cord injury-induced bradycardia. J Trauma Acute Care Surg 76(2):297–301 (Discussion 301–302). https://doi.org/10.1097/TA.0000000000000118
Lim-Hing K, Massetti J, Pajoumand M, Gupta S, Jenkins R, Hassan M, Paganelli P, Parikh G, Chang WT, Schwartzbauer G, Stein D, Badjatia N (2022) Impact of enteral albuterol on bradycardic events after acute cervical spinal cord injury. Neurocrit Care 36(3):840–845. https://doi.org/10.1007/s12028-021-01384-0
Rollstin A, Carey MC, Doherty G, Tawil I, Marinaro J (2016) Oral albuterol to treat symptomatic bradycardia in acute spinal cord injury. Intern Emerg Med 11(1):101–105. https://doi.org/10.1007/s11739-015-1324-3
Robinson BV, Ettedgui JA, Sherman FS (2001) Use of terbutaline in the treatment of complete heart block in the fetus. Cardiol Young 11(6):683–686. https://doi.org/10.1017/s1047951101001123
Yoshida H, Iwamoto M, Sakakibara H et al (2001) Treatment of fetal congenital complete heart block with maternal administration of beta-sympathomimetics (terbutaline): a case report. Gynecol Obstetric Invest 52(2):142–144
Chan AY, Silverman RK, Smith FC, Geifman-Holtzman O (1999) In utero treatment of fetal complete heart block with terbutaline. A case report. J Reprod Med 44(4):385–387
Cuneo BF, Lee M, Roberson D et al (2010) A management strategy for fetal immune-mediated atrioventricular block. J Matern Fetal Neonatal Med 23(12):1400–1405. https://doi.org/10.3109/14767051003728237
Sivarajah J, Huggon IC, Rosenthal E (2003) Successful management of fetal hydrops due to congenitally complete atrioventricular block. Cardiol Young 13(4):380–383
Jaeggi ET, Fouron JC, Silverman ED, Ryan G, Smallhorn J, Hornberger LK (2004) Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 110(12):1542–1548. https://doi.org/10.1161/01.CIR.0000142046.58632.3A
Groves AM, Allan LD, Rosenthal E (1995) Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Circulation 92(12):3394–3396. https://doi.org/10.1161/01.cir.92.12.3394
Funding
No funding was provided for this case series.
Author information
Authors and Affiliations
Contributions
AB wrote the main manuscript text and prepared the figures. AB and WP performed literature review and compiled the patient histories used for the clinical vignettes. All authors were involved in compiling the patient cases for this series, and reviewed the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflicts of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Butensky, A.M., Patten, W.F., Silver, E.S. et al. Oral Albuterol Treatment in Three Pediatric Patients with Bradycardia: A Novel Therapy. Pediatr Cardiol 45, 441–445 (2024). https://doi.org/10.1007/s00246-023-03379-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-023-03379-4